Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score

• Type of Material: Article
• Authors: Jane Meisel, Emory University; Chao Zhang, Emory University; Cameron Neely, Emory University; Pia Menduza, Emory University; Shuo You, Emory University; Tatiana Han, Emory University; Yuan Liu, Emory University; Aysegul A. Sahin, University of Texas MD Anderson Cancer Center; Ruth O'Regan, University of Wisconsin-Madison; Xiaoxian Li, Emory University
• Language: English
• Date: 2018-10-01
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2017 Elsevier Inc. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.clbc.2017.12.006
• Title of Journal or Parent Work: Clinical Breat Cancer
• Volume: 18
• Issue: 5
• Start Page: 347
• End Page: 352
• Grant/Funding Information: Supported in part by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and National Institutes of Health (NIH)-National Cancer Institute under award P30CA138292.
• Keywords: Disease-free survival; Metastasis; Expression; Women; Consensus; Life Sciences & Biomedicine; Oncology; Overall survival; Therapy; Benefit; Pathological complete response; Chemotherapy; ER positive; Worse; Disease free survival; Biomarkers; Science & Technology
• Research Categories: Biology, Bioinformatics; Health Sciences, Oncology; Health Sciences, Pathology; Health Sciences, Rehabilitation and Therapy; Biology, Biostatistics

Abstract

Patients in both the 1-10 group and the 11-18 group had good prognoses. Those who experienced recurrence were more likely to be premenopausal and to have failed to comply with the recommended endocrine therapy regimen. Endocrine therapy remains important in these patients. Introduction: Hormone receptor–positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor–positive, HER2-negative, lymph node–negative cancers with Oncotype DX score ranges of 1 to 10 (1-10 group) and 11 to < 18 (11-18 group). Patients and Methods: A total of 107 cases in the 1-10 group and 225 cases in the 11-18 group were reviewed. All patients received surgery. The use of chemotherapy, radiotherapy, and endocrine therapy, and overall survival (OS), disease-free survival (DFS), and distant metastasis were compared between groups. Results: There were no statistical differences in the use of chemotherapy (5.05% vs. 6.05%, P =.724) or radiotherapy (52.53% vs. 59.07%, P =.276) between the 1-10 group and the 11-18 group, respectively. The median OS and DFS were 47 and 45 months, respectively, in the 1-10 group, and 49 and 48 months in the 11-18 group. No significant difference was seen in OS (P =.995), DFS (P =.148), or rates of metastasis (P =.998). The 11-18 group had more death events and distant metastasis (death, 5 events; recurrence, 2 events; metastasis, 2 events) than the 1-10 group (death, 0 events; recurrence, 4 events; metastasis, 0 events). The majority of recurrences seen in both groups were in young patients who failed to comply with their endocrine therapy regimen. Conclusion: Patients in both the 1-10 group and the 11-18 group had good prognoses. Those who experienced recurrence were more likely to be premenopausal and to have failed to comply with the recommended endocrine therapy regimen. Endocrine therapy remains important in these patients.